The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Introduction Microalbuminuria and hypertension are risk factors for the development of diabetic nephropathy. Blockade of the renin-angiotensin system reduces progression to diabetic nephropathy in type 1 diabetic patients, whereas similar data are lacking for hypertensive type 2 diabetic subjects. We evaluated the renoprotective effect of an angiotensin II receptor antagonist, irbesartan, in hypertensive type 2 diabetic patients with microalbuminuria. Material and methods Five hundred and ninety hypertensive type 2 diabetic patients with microalbuminuria were enrolled in this multinational, randomised, double-blind, placebo-controlled study of irbesartan 150 mg/daily or 300 mg/daily or matching placebo for two years. The primary outcome was time to progression to diabetic nephropathy, defined as a persistent overnight albuminuria > 200 micrograms/min and at least a 30 per cent increase from baseline. Results Baseline characteristics in the three groups were similar. Ten patients (5.2 per cent) receiving irbesartan 300 mg and 19 patients (9.7 per cent) receiving irbesartan 150 mg daily reached the primary end point, as compared to 30 (14.9 per cent) patients on placebo (hazard ratio 0.30 [95 per cent confidence interval 0.14 to 0.61], p Discussions Irbesartan is renoprotective independently of its blood pressure lowering effect in type 2 diabetic subjects with microalbuminuria. It is safe and well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antihypertensive therapy reduces the risk of albuminuria (67)(68)(69)(70), and among people with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73m 2 and UACR $300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to ESKD (71)(72)(73)(74)(75)(76)(77)(78)(79)(80).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“In the setting of lower levels of albuminuria (30-299 mg/g creatinine), ACE inhibitor or ARB therapy at maximum tolerated doses in trials has reduced progression to more advanced albuminuria ($300 mg/g creatinine), slowed CKD progression, and reduced cardiovascular events but has not reduced progression to ESKD (74,77).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“The IRMA-2 study showed that treatment with irbesartan, an ARB, was associated with a dose-dependent reduction in the risk of progression of CKD, with an almost 3-fold risk reduction with the highest dose (300 mg per day) at 2 years of followup.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“This effect was independent of the blood pressure -lowering properties of irbesartan.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“In this regard, it should be noted that in related studies in patients with type 1 and type 2 diabetes, 1,28,29 the benefits of captopril or irbesartan were not tested in the presence of concurrent calcium-channel-antagonist therapy.”
From Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) · cites this paper as [29]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
The Effect of Age on Creatinine Clearance in Men: A Cross-sectional and Longitudinal Study
Rowe, J. W., Andres, R., Tobin, J. D., Norris, A. H., & Shock, N. W. (1976) · Journal of Gerontology · doi:10.1093/geronj/31.2.155 · Cited by 1,104
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Self-citationTatti, P., Pahor, M., Byington, R. P., Mauro, P. D., Guarisco, R., Strollo, G., & Strollo, F. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.597 · Cited by 850
Ravid, M., Savin, H., Jutrin, I., Bental, T., Katz, B., & Lishner, M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00001 · Cited by 775
Research works printed but not linked: 9
- Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. The kidney. 6th ed. Philadelphia: W.B. Saunders, 2000:1731-73.
- Hofman W, 1989, Lab Med, 13, 470
- Seelig HP, 1969, Z Klin Chem Klin Biochem, 7, 581
- Goldstein DE, 1986, Clin Chem, 32, B64
- 10.1001/jama.271.4.275 · doi:10.1001/jama.271.4.275 · Paper page
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1959, J Natl Cancer Inst, 27, 719
- Agardh C-D, 1996, J Hum Hypertens, 10, 185
- Estacio RO, 2000, Diabetes Care, 23, B54
Cited by
Items 901–1,000 of 1,008
Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
Nickenig, G., Östergren, J., & Struijker-Boudier, H. A. J. (2006) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2006.017 · Cited by 34
Hoogwerf, B. J., Sferra, J. J., & Donley, B. G. (2006) · Foot and Ankle Clinics · doi:10.1016/j.fcl.2006.06.014 · Cited by 29
Balancing the outcomes: reporting adverse events
KEECH, A. C., Wonders, S. M., Gebski, V., & Cook, D. I. (2004) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2004.tb06241.x · Cited by 31
Zanella, M. T., & Ribeiro, A. B. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80016-9 · Cited by 33
Yano, N., Suzuki, D., Endoh, M., Cao, T. N., Dahdah, J. R., Tseng, A., Stabila, J. P., McGonnigal, B., Padbury, J. F., & Tseng, Y. (2009) · Biochemical Journal · doi:10.1042/bj20082277 · Cited by 29
Imai, E., Haneda, M., Yamasaki, T., Kobayashi, F., Harada, A., Ito, S., Chan, J. C. N., & Makino, H. (2013) · Hypertension Research · doi:10.1038/hr.2013.86 · Cited by 29
Meeting the Challenge to Improve the Treatment of Hypertension in Blacks
Lopes, A. A., James, S. A., Port, F. K., OJO, A. O., Agodoa, L. Y. C., & Jamerson, K. (2003) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2003.01736.x · Cited by 36
Landelijke Transmurale Afspraak Chronische nierschade
Hah, K., & Cajm, G. (2009) · Cited by 29
Ricci, F., Castelnuovo, A. F. D., Savarese, G., Filardi, P. P., & Caterina, R. D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.132 · Cited by 31
Ofili, E., Ferdinand, K. C., Saunders, E., Neutel, J. M., Bakris, G. L., Cushman, W. C., Sowers, J. R., & Weber, M. A. (2006) · PubMed · Cited by 29
Manotham, K., Ongvilawan, B., Urusopone, P., Chetsurakarn, S., Tanamai, J., Limkuansuwan, P., Tungsanga, K., & Eiam‐Ong, S. (2011) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2011.02610.x · Cited by 29
Antiproteinuric Effect of an N-Type Calcium Channel Blocker, Cilnidipine
Tsuchihashi, T., Ueno, M., Tominaga, M., Kajioka, T., Onaka, U., Eto, K., & Gotō, K. (2005) · Clinical and Experimental Hypertension · doi:10.1080/10641960500298558 · Cited by 29
World Kidney Day 2010: Diabetic Kidney Disease—Act Now or Pay Later
Atkins, R. C., & Zimmet, P. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.12.001 · Cited by 35
Kyotani, Y., Zhao, J., Tomita, S., Nakayama, H., Isosaki, M., Uno, M., & Yoshizumi, M. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09332fp · Cited by 29
Reversal of renal disease: is it enough to inhibit the action of angiotensin II?
Jc, D., & Chatziantoniou, C. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402143 · Cited by 30
Zandbergen, A. A. M., Vogt, L., de Zeeuw, D., Lamberts, S. W. J., Ouwendijk, R. J. T., Baggen, M. G. A., & Bootsma, A. H. (2007) · Diabetes Care · doi:10.2337/dc07-0960 · Cited by 33
Progression of Renal Failure – The Role of Hypertension
Whitworth, J. A. (2005) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v34n1p8 · Cited by 29
Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats
Janiak, P., Bidouard, J., Cadrouvele, C., Poirier, B., Gouraud, L., Grataloup, Y., Pierre, F., Bruneval, P., O'Connor, S. E., & Herbert, J. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.01.032 · Cited by 32
Appel, G. B., & Appel, A. S. (2004) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2004.04.005 · Cited by 29
Intrarenal Hemodynamic Changes After Captopril Test in Patients With Type 2 Diabetes
Taniwaki, H., Ishimura, E., Kawagishi, T., Matsumoto, N., Hosoi, M., Emoto, M., Shoji, T., Shoji, S., Nakatani, T., Inaba, M., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.132 · Cited by 29
Weir, M. R. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03050509 · Cited by 32
Cost-Effective Strategies in the Prevention of Diabetic Nephropathy
Rippin, J. D., Barnett, A. H., & Bain, S. C. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422010-00002 · Cited by 29
The Renoprotective Potential of Pentoxifylline in Chronic Kidney Disease
Lin, S., Chiang, W., Chen, Y., Lai, C., Tsai, T., & Hsieh, B. (2005) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(09)70228-x · Cited by 30
Comparative Effects of Irbesartan on Ambulatory and Office Blood Pressure
Rossing, K., Christensen, P. K., Andersen, S., Hovind, P. H., Hansen, H. P., & Parving, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.569 · Cited by 29
Self-citationRenal dysfunction in heart failure patients: what is the evidence?
SALTZMAN, H. E., Sharma, K., Mather, P. J., Rubin, S., Adams, S., & Whellan, D. J. (2007) · Heart Failure Reviews · doi:10.1007/s10741-007-9006-5 · Cited by 28
Murayama, S., Hirano, T., Sakaue, T., Okada, K., IKEJIRI, R., & Adachi, M. (2003) · Hypertension Research · doi:10.1291/hypres.26.453 · Cited by 29
Imai, S., Momo, K., Kashiwagi, H., Miyai, T., Sugawara, M., & Takekuma, Y. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5027 · Cited by 28
Ferrari, R. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802576302 · Cited by 31
Sulodexide and glycosaminoglycans in the progression of renal disease
Masola, V., Zaza, G., & Gambaro, G. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft389 · Cited by 28
“Furthermore, in a 2-year followup trial in Type 2 diabetic patients with incipient nephropathy treated with irbesartan, progression to overt nephropathy was prevented only in 1 out of 10 patients [52].”
BackgroundGong, M., Guo, Y., Dong, H., Wu, W., Wu, F., & Lu, F. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115747 · Cited by 31
Morales, E., Caro, J., Gutiérrez, E., Sevillano, Á., Auñón, P., Fernández, C., & Praga, M. (2015) · Kidney International · doi:10.1038/ki.2015.249 · Cited by 34
Wiederkehr, M. R., Toto, R. D., Fenves, A. Z., & Ram, C. V. S. (2005) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2005.02.008 · Cited by 30
Derosa, G., Cicero, A. F. G., Gaddi, A. V., Mugellini, A., Ciccarelli, L., & Fogari, R. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000161403.91456.39 · Cited by 28
Role of ACE Inhibitors in Patients with Diabetes Mellitus
Cordonnier, D., Zaoui, P., & Halimi, S. (2001) · Drugs · doi:10.2165/00003495-200161130-00001 · Cited by 52
From JNC I to JNC 7—What Have We Learned?
Moser, M. (2006) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.02.003 · Cited by 34
Benefits of Antihypertensive Pharmacologic Therapy and Blood Pressure Reduction in Outcome Trials
Wang, J., & Staessen, J. A. (2003) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2003.01307.x · Cited by 28
Zillich, A. J., Saseen, J. J., DeHart, R. M., Dumo, P., Grabe, D. W., Gilmartin, C., Hachey, D. M., Hudson, J. Q., Pruchnicki, M. C., & Joy, M. S. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.1.123.55628 · Cited by 31
Wang, Y., Shi, L., Wang, L.-Y., Xu, J., & Feng, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922473 · Cited by 28
“Unfortunately, most of them have been reported to have only limited beneficial effect during long-term treatment [10,11].”
Choice of anti-hypertensive agents in diabetic subjects
Patel, B. M., & Mehta, A. A. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113485250 · Cited by 33
Chen, Y., Gong, Z., Cai, G., Gao, Q., Chen, X., Li, T., Wei, R., & Zhou, J. (2014) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-014-1891-6 · Cited by 28
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Plutzky, J., & Boulton, A. J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00033-2 · Cited by 44
The elderly patient with chronic kidney disease
Hansberry, M. R., Whittier, W. L., & Krause, M. W. (2005) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2004.10.013 · Cited by 37
Therapeutic measures in proteinuric nephropathy
Praga, M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09925.x · Cited by 31
Tabrizchi, R. (2003) · Drugs · doi:10.2165/00003495-200363200-00003 · Cited by 36
Martin, J. H., & Krum, H. (2002) · Pharmacological Research · doi:10.1016/s1043-6618(02)00092-0 · Cited by 28
Harris, S. B., & Lank, C. N. (2004) · PubMed · Cited by 32
Angiotensin‐Converting Enzyme Inhibitors and Type 2 Diabetic Nephropathy: A Meta‐Analysis
Hamilton, R. A., Kane, M. P., & Demers, J. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.7.909.32726 · Cited by 28
Thielen, S. C., Reusch, J. E. B., & Regensteiner, J. G. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1218692 · Cited by 41
Chida, R., Hisauchi, I., Toyoda, S., Kikuchi, M., Komatsu, T., Hori, Y., Nakahara, S., Sakai, Y., Inoue, T., & Taguchi, I. (2015) · Hypertension Research · doi:10.1038/hr.2015.82 · Cited by 32
Manni, M. E., Bigagli, E., Lodovici, M., Zazzeri, M., & Raimondi, L. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.11.010 · Cited by 27
“Then, since AT1 antagonists represent the gold standard treatments for DN [12–14], we aimed to investigate the effect of losartan treatment of diabetic rats on MAO activity in the context of the kidney antioxidant defences and of oxidative injuries to lipids and proteins.”
BackgroundRomanelli, R. J., Schiro, T. A., Jukes, T., Wong, K. S., & Ishisaka, D. Y. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q523 · Cited by 27
Nishida, Y., Takahashi, Y., Nakayama, T., Soma, M., & Asai, S. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-74 · Cited by 27
Cannabinoid Receptors in Diabetic Kidney Disease
Barutta, F., Mastrocola, R., Bellini, S., Bruno, G., & Gruden, G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0975-7 · Cited by 29
Montero, D., Díaz-Cañestro, C., Oberholzer, L., & Lundby, C. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30119-6 · Cited by 31
Enfermedad renal crónica: clasificación, mecanismos de progresión y estrategias de renoprotección
Mezzano, S. A., & Aros, C. (2005) · Revista médica de Chile · doi:10.4067/s0034-98872005000300011 · Cited by 29
Østergaard, J. A., Thiel, S., Hovind, P. H., Holt, C. B., Parving, H., Flyvbjerg, A., Rossing, P. R., & Hansen, T. K. (2014) · Diabetologia · doi:10.1007/s00125-014-3332-7 · Cited by 28
Self-citationComparing angiotensin II receptor blockers on benefits beyond blood pressure
Siragy, H. M. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0028-3 · Cited by 29
Twenty-five Facts about Kidney Disease in Singapore: In Remembrance of World Kidney Day
Vathsala, A. (2007) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v36n3p157 · Cited by 27
Rabbani, N., Adaikalakoteswari, A., Rossing, K., Rossing, P. R., Tarnow, L., Parving, H., & Thornalley, P. J. (2011) · Amino Acids · doi:10.1007/s00726-011-0857-7 · Cited by 27
Self-citationSud, M. K., Tangri, N., Pintilie, M., Levey, A. S., & Naimark, D. M. J. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv389 · Cited by 28
Variability in response to albuminuria‐lowering drugs: true or random?
Petrykiv, S. I., de Zeeuw, D., Persson, F., Rossing, P. R., Gansevoort, R. T., Laverman, G. D., & Heerspink, H. J. L. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13217 · Cited by 27
“Data sources Day-to-day variability in albuminuria To assess the day-to-day variability in albuminuria we calculated the intra-individual coefficient of variation in the placebo arms of PREVEND-IT, BENEDICT, IRMA-2, and RENAAL clinical trials.[9-12] The characteristics of the included populations are described elsewhe…”
MethodResultThomopoulos, C., Parati, G., & Zanchetti, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001548 · Cited by 30
Jacobsen, P. K., Rossing, K., & Parving, H. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200405000-00009 · Cited by 27
Self-citationThe Role of Olmesartan Medoxomil in the Management of Hypertension
Unger, T., McInnes, G. T., Neutel, J. M., & B�hm, M. (2004) · Drugs · doi:10.2165/00003495-200464240-00002 · Cited by 27
Karagiannis, A. I., Mikhailidis, D. P., Athyros, V. G., Kakafika, A. I., Τζιόμαλος, Κ., Liberopoulos, E. N., Florentin, M., & Elisaf, M. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.191 · Cited by 29
Saito, I., Kobayashi, M., MATSUSHITA, Y., Mori, A., Kawasugi, K., & Saruta, T. (2008) · Hypertension Research · doi:10.1291/hypres.31.1373 · Cited by 30
Recent changes in the landscape of combination RAS blockade
Epstein, B. J., Smith, S. M., & Choksi, R. R. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.127 · Cited by 27
Kurokawa, K., Chan, J. C. N., Cooper, M. E., Keane, W. F., Shahinfar, S., & Zhang, Z. (2006) · Clinical and Experimental Nephrology · doi:10.1007/s10157-006-0427-6 · Cited by 29
Boersma, C., Thobari, J. A., Gansevoort, R. T., den Berg, L. T. W. D. J., de Jong, P. E., de Zeeuw, D., Annemans, L., & Postma, M. J. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624060-00001 · Cited by 27
Perico, N., Codreanu, I., Schieppati, A., & Remuzzi, G. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09716.x · Cited by 27
Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes
Hockensmith, M. L., Estacio, R. O., Mehler, P. S., Havranek, E. P., Ecder, T., Lundgren, R. A., & Schrier, R. W. (2004) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2003.09.003 · Cited by 29
SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabeticdb/dbmice
Sugaru, E., Nakagawa, T., Ono‐Kishino, M., Nagamine, J., Tokunaga, T., Kitoh, M., Hume, W. E., Nagata, R., & Taiji, M. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00357.2005 · Cited by 26
Measuring Albuminuria in Individuals With Obesity: Pitfalls of the Urinary Albumin-Creatinine Ratio
Chagnac, A., & Friedman, A. N. (2024) · Kidney Medicine · doi:10.1016/j.xkme.2024.100804 · Cited by 35
Sato, A. (2015) · Hypertension Research · doi:10.1038/hr.2015.19 · Cited by 26
Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals
Taverny, G., Mimouni, Y., LeDigarcher, A., Chevalier, P., Thijs, L., Wright, J. M., & Gueyffier, F. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011745.pub2 · Cited by 33
Jadawji, C., Crasto, W., Gillies, C. L., Kar, D., Davies, M. J., Khunti, K. K., & Seidu, S. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13569 · Cited by 27
Long, B., Wan, Y., Zhang, S., & Lv, L. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1854307 · Cited by 26
“However, clinical trials showed increased adverse events of RAS inhibitors, like increased cardiovascular events, and fewer benefits in preventing end-stage kidney disease (Lewis et al. 1993, Parving et al. 2001).”
BackgroundAngiotensin II receptor blockers in the treatment of the cardiovascular disease continuum
Chrysant, S. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.12.002 · Cited by 26
Adarkwah, C. C., Gandjour, A., Akkerman, M. K., & Evers, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026139 · Cited by 31
“68 – [46,47] applied to all health states except for ESRD”
BackgroundMethodManaging hypertension in patients with type 2 diabetes mellitus
Dobesh, P. P. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050385 · Cited by 33
Irbesartan: A Review of its Use in Hypertension and Diabetic Nephropathy
Croom, K. F., & Plosker, G. L. (2008) · Drugs · doi:10.2165/00003495-200868110-00008 · Cited by 28
Weinberg, M. S., Kaperonis, N., & Bakris, G. L. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0088-8 · Cited by 28
Hellemons, M. E., Denig, P., de Zeeuw, D., Voorham, J., & Heerspink, H. J. L. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs567 · Cited by 26
“Known duration of diabetes, years 14 120 (100) 6 [3–10] 6 [3–10] 6 [3–9] <0.”
BackgroundHartner, A., Cordasic, N., Klanke, B., Wittmann, M., Veelken, R. A., & Hilgers, K. F. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00088.2006 · Cited by 26
Espinel, E., Joven, J., Nuñez-Gil, I. J., Suñé, P., Renedo, B., Fort, J., & Serón, D. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-306 · Cited by 26
Syed, S. T., Sharp, L. K., Kim, Y., Jentleson, A., Lora, C. M., Touchette, D. R., Berbaum, M. L., Suda, K. J., & Gerber, B. S. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1757 · Cited by 28
Mohamed, E. A., Ahmed, H. I., & Zaky, H. S. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2018-0259 · Cited by 26
Hughes, D. B., & Britton, M. L. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.11.1602 · Cited by 28
Fogari, R., Derosa, G., Zoppi, A., Rinaldi, A., Preti, P. S., Lazzari, P., & Mugellini, A. (2008) · Hypertension Research · doi:10.1291/hypres.31.43 · Cited by 27
Saunders, E., Cable, G., & Neutel, J. (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2007.07195.x · Cited by 28
Haneda, M., Kikkawa, R., Sakai, H., & Kawamori, R. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.02.015 · Cited by 26
Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria
Delea, T. E., Sofrygin, O., Palmer, J. L., Lau, H., Munk, V. C., Sung, J., Charney, A., Parving, H., & Sullivan, S. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008111144 · Cited by 26
Self-citationSeccia, T. M., Belloni, A. S., Guidolin, D., Sticchi, D., Nussdorfer, G. G., Pessina, A. C., & Rossi, G. P. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000234124.94013.ac · Cited by 26
Bakris, G. L. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.013 · Cited by 26
The renin angiotensin system as a therapeutic target to prevent diabetes and its complications
Vijayaraghavan, K., & DEEDWANIA, P. C. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2004.11.003 · Cited by 24
Knudsen, S. T., Bek, T., Poulsen, P. L., Hove, M. N., Rehling, M., & Mogensen, C. E. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01192.x · Cited by 26
Diabetic nephropathy: a global and growing threat.
Tang, S. C. W. (2010) · PubMed · Cited by 29
Varughese, G. I., & Lip, G. Y. H. (2005) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001833 · Cited by 25
“The beneficial effect of blockade of the renin–angiotensin–aldosterone system (RAAS) is therefore not only for blood pressure reduction but also for end-organ protection in patients with type-II diabetes”
Treatment and practical considerations of diabetic kidney disease
Bilen, Y., Almoushref, A., Alkwatli, K., Osman, O., Mehdi, A., & Sawaf, H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1264497 · Cited by 29
The Pathogenesis and Management of Hypertension in Diabetic Kidney Disease
Buren, P. N. V., & Toto, R. D. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.10.003 · Cited by 30
Metadata
- Authors
- Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- University Hospital Magdeburg (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-09-20
- Volume
- 345
- Issue
- 12
- Pages
- 870-878
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003670762
- Semantic Scholar
- bec1f00c2120232a55a25b7d846d63e92a3ff8fc
- Cited by
- 2,873
- References
- 26
- Citations by year
- 2026: 30 · 2025: 44 · 2024: 50 · 2023: 61 · 2022: 61 · 2021: 58 · 2020: 63 · 2019: 50 · 2018: 63 · 2017: 71 · 2016: 84 · 2015: 88 · 2014: 105 · 2013: 103 · 2012: 117
- FWCI
- 146.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- irbesartan, diabetic nephropathy, type 2 diabetes, hypertension, microalbuminuria, renal protection, angiotensin receptor blockers, renin-angiotensin system blockade, albuminuria, blood pressure, dose comparison, adverse events, renin-angiotensin system inhibitors
- MeSH terms
- Irbesartan, Adult, Aged, Albuminuria, Antihypertensive Agents, Biphenyl Compounds, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Tetrazoles, Proportional Hazards Models, Disease Progression, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.